Skip to main content
. Author manuscript; available in PMC: 2015 Jan 28.
Published in final edited form as: Cancer Lett. 2014 Oct 18;356(2 0 0):656–668. doi: 10.1016/j.canlet.2014.10.015

Table 1.

Effect of MK-1775 on panobinostat sensitivities in pancreatic cancer cell lines.

Cell line IC50 of MK-1775 (μM) IC50 of panobinostat (nM) in the absence or presence of MK-1775 (μM)
p Value#
0 0.13 0.25 0.5
ASPC-1 13.2 ± 1.1*   94.6 ± 9.2   58.5 ± 6.3
(0.63)
  56.7 ± 4.8
(0.62)
  53.3 ± 3.7
(0.6)
<0.05
BxPC-3   0.8 ± 0.03   37.8 ± 2.2   16.2 ± 0.8
(0.59)
  13.2 ± 1.1
(0.66)
  11. 9 ± 1.0
(0.95)
<0.001
CFPAC-1   3.3 ± 0.2 407.6 ± 14.0 263.4 ± 19.9
(0.68)
246.1 ± 7.6
(0.68)
224.5 ± 5.0
(0.7)
<0.005
HPAC   0.5 ± 0.01   81.7 ± 7.8   50.2 ± 1.6
(0.88)
  28.4 ± 1. 6
(0.88)
ND <0.05
MIAPaCa-2   0.5 ± 0.05   36.0 ± 2.7   21.2 ± 1.5
(0.82)
  16.1 ± 1. 5
(0.91)
ND <0.05
PANC-1 10.6 ± 1.1* 569.6 ± 13.4* 397.7 ± 23.0
(0.71)
378.6 ± 24.3
(0.69)
325.4 ± 21.6
(0.62)
<0.005

Note: MK-1775 and panobinostat IC50s are presented as means ± standard errors from at least three independent experiments. Numbers in parentheses represent the combination index values.

ND – not determined.

*

indicates estimated IC50 calculated by using GraphPad Prism 5.0 software.

#

indicates that p values for each pair were determined using GraphPad Prism 5.0 and only the largest p value is shown for each cell line.